Want to see TSE:RX full AI Analyst Report?
RX Stock Chart & Stats
C$14.80
C$0.00(0.00%)
At close: 4:00 PM EST
C$14.80
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$10.65 - C$15.80
Previous CloseN/A
Volume6.04K
Average Volume (3M)5.67K
Market Cap
C$165.86M
Enterprise ValueC$157.64M
Total Cash (Recent Filing)C$10.90M
Total Debt (Recent Filing)C$5.25M
Price to Earnings (P/E)17.9
Beta0.76
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.6%
Share Statistics
EPS (TTM)0.81
Shares Outstanding11,438,318
10 Day Avg. Volume6,048
30 Day Avg. Volume5,666
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.00Price Target Upside21.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.94
Revenue Forecast (FY)C$68.60M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and operating margins indicate durable product-level economics and pricing power from in-licensed therapies. Strong margins support reinvestment into commercialization, partner payments and improve resilience to pricing pressure, bolstering long-term cash generation and ROE.
Conservative Balance SheetExtremely low leverage provides meaningful financial flexibility for licensing deals, working capital swings and opportunistic M&A, while minimizing refinancing risk. This enhances durability through industry cycles and supports steady operational funding without heavy interest burden.
Strong Cash GenerationOperating cash flow consistently exceeding net income and a sharp FCF rebound show high earnings quality and real cash conversion. Reliable cash generation underpins funding for partner milestones, commercialization investment, dividends or buybacks and reduces reliance on external financing.
Bears Say
Uneven Revenue CadenceRevenue has been lumpy historically, reflecting reliance on timing of in-licensed product launches and renewals. This uneven top-line makes forecasting and multi-period growth assumptions less certain, potentially increasing funding timing risk for commercialization investments and partner payouts.
FCF VolatilityMaterial swings in free cash flow, driven by working capital or investment timing, reduce predictability of internally available funds. For a small commercial model that pays partner fees or milestones, volatility can constrain the pace of new licensing deals or necessitate short-term financing in weaker quarters.
Concentration & Partnership RiskBusiness depends on in-licensed products and partner contracts; limited disclosure on partner terms or product concentration raises risk that loss or underperformance of a few products could materially impact revenue and margins, reducing long-term predictability of cash flows.
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$10.65 and its highest was C$15.80 in the past 12 months.
What is Biosyent Inc’s market cap?
Biosyent Inc’s market cap is C$165.86M.
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is Aug 25, 2026 which is in 54 days.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on May 14, 2026. The company reported C$0.2 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.2.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.055 which represents an annual dividend yield of 1.6%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,438,318 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.07%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biosyent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$18.00 (21.62% Upside)
C$18.00 (21.62% Upside)
Insider Transactions
Sold Shares
Worth C$440.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.79%
12-Months-Change
Fundamentals
Return on Equity
22.05%
Trailing 12-Months
Asset Growth
46.14%
Trailing 12-Months
Company Description
Biosyent Inc
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
RX Stock 12 Month Forecast
Average Price Target
C$18.00
▲(21.62% Upside)
Technical Analysis
Aequus Pharmaceuticals
―
Willow Biosciences Inc
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---